These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30426647)

  • 1. Improved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery.
    Huynh V; Jesmer AH; Shoaib MM; D'Angelo AD; Rullo AF; Wylie RG
    Chembiochem; 2019 Mar; 20(6):747-753. PubMed ID: 30426647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-time evaluation of a hydrogel delivery vehicle for cancer immunotherapeutics within embedded spheroid cultures.
    Huynh V; Tatari N; Marple A; Savage N; McKenna D; Venugopal C; Singh SK; Wylie R
    J Control Release; 2022 Aug; 348():386-396. PubMed ID: 35644288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer-based hydrogels with local drug release for cancer immunotherapy.
    Xie Z; Shen J; Sun H; Li J; Wang X
    Biomed Pharmacother; 2021 May; 137():111333. PubMed ID: 33571834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery.
    Jin Q; Liu Z; Chen Q
    J Control Release; 2021 Jan; 329():882-893. PubMed ID: 33053396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immune-Based Combination Therapy.
    Ma H; He C; Chen X
    Macromol Biosci; 2021 Jun; 21(6):e2100039. PubMed ID: 33818918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable Hydrogels as Unique Platforms for Local Chemotherapeutics-Based Combination Antitumor Therapy.
    Yu S; He C; Chen X
    Macromol Biosci; 2018 Dec; 18(12):e1800240. PubMed ID: 30303620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomaterial-Based Sustained-Release Drug Formulations for Localized Cancer Immunotherapy.
    Mujahid K; Rana I; Suliman IH; Li Z; Wu J; He H; Nam J
    ACS Appl Bio Mater; 2024 Aug; 7(8):4944-4961. PubMed ID: 38050811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homophilic antibodies as immunotherapeutics.
    Kohler H
    Immunotherapy; 2013 Mar; 5(3):235-46. PubMed ID: 23444953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer.
    Mikhail AS; Morhard R; Mauda-Havakuk M; Kassin M; Arrichiello A; Wood BJ
    Adv Drug Deliv Rev; 2023 Nov; 202():115083. PubMed ID: 37673217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled-release and local delivery of therapeutic antibodies.
    Grainger DW
    Expert Opin Biol Ther; 2004 Jul; 4(7):1029-44. PubMed ID: 15268671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing Hydrogels for On-Demand Therapy.
    Oliva N; Conde J; Wang K; Artzi N
    Acc Chem Res; 2017 Apr; 50(4):669-679. PubMed ID: 28301139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer.
    Chua CYX; Jain P; Susnjar A; Rhudy J; Folci M; Ballerini A; Gilbert A; Singh S; Bruno G; Filgueira CS; Yee C; Butler EB; Grattoni A
    J Control Release; 2018 Sep; 285():23-34. PubMed ID: 30008369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.
    Fransen MF; Cordfunke RA; Sluijter M; van Steenbergen MJ; Drijfhout JW; Ossendorp F; Hennink WE; Melief CJ
    Vaccine; 2014 Mar; 32(15):1654-60. PubMed ID: 24508038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.
    Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
    Biomaterials; 2015 Aug; 61():33-40. PubMed ID: 25993015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
    Chester C; Marabelle A; Houot R; Kohrt HE
    Curr Opin Immunol; 2015 Apr; 33():1-8. PubMed ID: 25576932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled delivery of antibodies from injectable hydrogels.
    Fletcher NA; Babcock LR; Murray EA; Krebs MD
    Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():801-806. PubMed ID: 26652435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research progress on hydrogel-based drug therapy in melanoma immunotherapy.
    He W; Zhang Y; Qu Y; Liu M; Li G; Pan L; Xu X; Shi G; Hao Q; Liu F; Gao Y
    BMB Rep; 2024 Feb; 57(2):71-78. PubMed ID: 38053295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
    Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.